FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements

On August 26, 2011, crizotinib received accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by a test approved by the U.S. Food and Drug Administration (FDA). Approval was based on two single-arm t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kazandjian, Dickran, Blumenthal, Gideon M., Chen, Huan-Yu, He, Kun, Patel, Mona, Justice, Robert, Keegan, Patricia, Pazdur, Richard
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: AlphaMed Press 2014
Pynciau:
Regulatory Issues: FDA
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201002/
https://ncbi.nlm.nih.gov/pubmed/25170012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0241
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg